Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K, Sekine Y, Osawa T, Naito S, Tokairin O, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Yamamoto R, Nara T, Saito M, Narita S, Akashi H, Tsuchiya N, Shinohara N, Habuchi T. Numakura K, et al. Among authors: naito s. Int J Clin Oncol. 2024 Jul;29(7):1019-1026. doi: 10.1007/s10147-024-02538-8. Epub 2024 May 26. Int J Clin Oncol. 2024. PMID: 38797782
Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S, Nishida H, Ito H, Fukuhara H, Nawano T, Narisawa T, Kanno H, Yagi M, Yamagishi A, Sakurai T, Naito S, Kato T, Morikane K, Tsuchiya N. Takai S, et al. Among authors: naito s. Front Immunol. 2022 Nov 30;13:1050211. doi: 10.3389/fimmu.2022.1050211. eCollection 2022. Front Immunol. 2022. PMID: 36532067 Free PMC article.
Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kurokawa M, Naito S, Kato T, Ushijima M, Yamagishi A, Sakurai T, Nishida H, Tsuchiya N. Kurokawa M, et al. Among authors: naito s. Asian J Urol. 2023 Jan;10(1):103-105. doi: 10.1016/j.ajur.2022.01.005. Epub 2022 Jul 16. Asian J Urol. 2023. PMID: 36721690 Free PMC article. No abstract available.
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi‑institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Kato R, et al. Among authors: naito s. Int J Clin Oncol. 2023 May;28(5):726-727. doi: 10.1007/s10147-023-02331-z. Int J Clin Oncol. 2023. PMID: 37010622 Free PMC article. No abstract available.
1,840 results